

Neuroendocrine Tumor Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

https://marketpublishers.com/r/N33044DAEBB7EN.html

Date: January 2021

Pages: 103

Price: US\$ 3,000.00 (Single User License)

ID: N33044DAEBB7EN

Abstracts

SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.


Chapter 12: Industry Summary.

The global Neuroendocrine Tumor Treatment market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Neuroendocrine Tumor Treatment market segmented into

Everolimus





Exelixis, Inc.



Advanced Accelerator Applications

Dauntless Pharmaceuticals, Inc.

Hutchinson Medipharma Limited

Ispen

Novartis AG

Progenics Pharmaceuticals, Inc.

Tarveda Therapeutics



Contents

1 RESEARCH SCOPE

- 1.1 Research Product Definition
- 1.2 Research Segmentation
 - 1.2.1 Product Type
 - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

2 GLOBAL NEUROENDOCRINE TUMOR TREATMENT INDUSTRY

- 2.1 Summary about Neuroendocrine Tumor Treatment Industry
- 2.2 Neuroendocrine Tumor Treatment Market Trends
 - 2.2.1 Neuroendocrine Tumor Treatment Production & Consumption Trends
- 2.2.2 Neuroendocrine Tumor Treatment Demand Structure Trends
- 2.3 Neuroendocrine Tumor Treatment Cost & Price

3 MARKET DYNAMICS

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
 - 3.2.1 Drivers
 - 3.2.2 Restraints
 - 3.2.3 Opportunity
 - 3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

- 4.1 Region Segmentation (2017 to 2021f)
 - 4.1.1 North America (U.S., Canada and Mexico)
 - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
- 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
 - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
- 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
- 4.2 Product Type Segmentation (2017 to 2021f)



- 4.2.1 Everolimus
- 4.2.2 Sunitinib
- 4.2.3 Lu-Dotatate
- 4.2.4 Lanreotide
- 4.2.5 Octreotide
- 4.3 Consumption Segmentation (2017 to 2021f)
 - 4.3.1 Hospitals
 - 4.3.2 Clinic
 - 4.3.3 Others

5 NORTH AMERICA MARKET SEGMENT

- 5.1 Region Segmentation (2017 to 2021f)
 - 5.1.1 U.S.
 - 5.1.2 Canada
 - 5.1.3 Mexico
- 5.2 Product Type Segmentation (2017 to 2021f)
 - 5.2.1 Everolimus
 - 5.2.2 Sunitinib
 - 5.2.3 Lu-Dotatate
 - 5.2.4 Lanreotide
 - 5.2.5 Octreotide
- 5.3 Consumption Segmentation (2017 to 2021f)
 - 5.3.1 Hospitals
 - 5.3.2 Clinic
 - 5.3.3 Others
- 5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

- 6.1 Region Segmentation (2017 to 2021f)
 - 6.1.1 Germany
 - 6.1.2 UK
 - 6.1.3 France
 - 6.1.4 Italy
 - 6.1.5 Rest of Europe
- 6.2 Product Type Segmentation (2017 to 2021f)
 - 6.2.1 Everolimus
 - 6.2.2 Sunitinib



- 6.2.3 Lu-Dotatate
- 6.2.4 Lanreotide
- 6.2.5 Octreotide
- 6.3 Consumption Segmentation (2017 to 2021f)
 - 6.3.1 Hospitals
 - 6.3.2 Clinic
 - 6.3.3 Others
- 6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

- 7.1 Region Segmentation (2017 to 2021f)
 - 7.1.1 China
 - 7.1.2 India
 - 7.1.3 Japan
 - 7.1.4 South Korea
 - 7.1.5 Southeast Asia
 - 7.1.6 Australia
 - 7.1.7 Rest of Asia Pacific
- 7.2 Product Type Segmentation (2017 to 2021f)
 - 7.2.1 Everolimus
 - 7.2.2 Sunitinib
 - 7.2.3 Lu-Dotatate
 - 7.2.4 Lanreotide
 - 7.2.5 Octreotide
- 7.3 Consumption Segmentation (2017 to 2021f)
 - 7.3.1 Hospitals
 - 7.3.2 Clinic
 - 7.3.3 Others
- 7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

- 8.1 Region Segmentation (2017 to 2021f)
 - 8.1.1 Brazil
 - 8.1.2 Argentina
 - 8.1.3 Rest of Latin America
- 8.2 Product Type Segmentation (2017 to 2021f)
 - 8.2.1 Everolimus



- 8.2.2 Sunitinib
- 8.2.3 Lu-Dotatate
- 8.2.4 Lanreotide
- 8.2.5 Octreotide
- 8.3 Consumption Segmentation (2017 to 2021f)
 - 8.3.1 Hospitals
 - 8.3.2 Clinic
 - 8.3.3 Others
- 8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

- 9.1 Region Segmentation (2017 to 2021f)
 - 9.1.1 GCC
 - 9.1.2 North Africa
 - 9.1.3 South Africa
 - 9.1.4 Rest of Middle East and Africa
- 9.2 Product Type Segmentation (2017 to 2021f)
 - 9.2.1 Everolimus
 - 9.2.2 Sunitinib
 - 9.2.3 Lu-Dotatate
 - 9.2.4 Lanreotide
 - 9.2.5 Octreotide
- 9.3 Consumption Segmentation (2017 to 2021f)
 - 9.3.1 Hospitals
 - 9.3.2 Clinic
 - 9.3.3 Others
- 9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

- 10.1 Brief Introduction of Major Players
 - 10.1.1 Exelixis, Inc.
 - 10.1.2 Advanced Accelerator Applications
 - 10.1.3 Dauntless Pharmaceuticals, Inc.
 - 10.1.4 Hutchinson Medipharma Limited
 - 10.1.5 Ispen
 - 10.1.6 Novartis AG
 - 10.1.7 Progenics Pharmaceuticals, Inc.



- 10.1.8 Tarveda Therapeutics
- 10.2 Neuroendocrine Tumor Treatment Sales Date of Major Players (2017-2020e)
 - 10.2.1 Exelixis, Inc.
 - 10.2.2 Advanced Accelerator Applications
 - 10.2.3 Dauntless Pharmaceuticals, Inc.
 - 10.2.4 Hutchinson Medipharma Limited
 - 10.2.5 Ispen
 - 10.2.6 Novartis AG
 - 10.2.7 Progenics Pharmaceuticals, Inc.
 - 10.2.8 Tarveda Therapeutics
- 10.3 Market Distribution of Major Players
- 10.4 Global Competition Segmentation

11 MARKET FORECAST

- 11.1 Forecast by Region
- 11.2 Forecast by Demand
- 11.3 Environment Forecast
 - 11.3.1 Impact of COVID-19
 - 11.3.2 Geopolitics Overview
 - 11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT



List Of Tables

LIST OF TABLES

- 1. Table Neuroendocrine Tumor Treatment Product Type Overview
- 2. Table Neuroendocrine Tumor Treatment Product Type Market Share List
- 3. Table Neuroendocrine Tumor Treatment Product Type of Major Players
- 4. Table Brief Introduction of Exelixis, Inc.
- 5. Table Brief Introduction of Advanced Accelerator Applications
- 6. Table Brief Introduction of Dauntless Pharmaceuticals, Inc.
- 7. Table Brief Introduction of Hutchinson Medipharma Limited
- 8. Table Brief Introduction of Ispen
- 9. Table Brief Introduction of Novartis AG
- 10. Table Brief Introduction of Progenics Pharmaceuticals, Inc.
- 11. Table Brief Introduction of Tarveda Therapeutics
- 12. Table Products & Services of Exelixis, Inc.
- 13. Table Products & Services of Advanced Accelerator Applications
- 14. Table Products & Services of Dauntless Pharmaceuticals, Inc.
- 15. Table Products & Services of Hutchinson Medipharma Limited
- 16. Table Products & Services of Ispen
- 17. Table Products & Services of Novartis AG
- 18. Table Products & Services of Progenics Pharmaceuticals, Inc.
- 19. Table Products & Services of Tarveda Therapeutics
- 20. Table Market Distribution of Major Players
- 21. Table Global Major Players Sales Revenue (Million USD) 2017-2020e
- 22. Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
- 23. Table Global Neuroendocrine Tumor Treatment Market Forecast (Million USD) by Region 2021f-2026f
- 24. Table Global Neuroendocrine Tumor Treatment Market Forecast (Million USD) Share by Region 2021f-2026f
- 25. Table Global Neuroendocrine Tumor Treatment Market Forecast (Million USD) by Demand 2021f-2026f
- 26. Table Global Neuroendocrine Tumor Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f



List Of Figures

LIST OF FIGURES

- 1. Figure Global Neuroendocrine Tumor Treatment Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
- 2. Figure Global Neuroendocrine Tumor Treatment Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
- 3. Figure Global Neuroendocrine Tumor Treatment Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
- 4. Figure Global Neuroendocrine Tumor Treatment Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
- 5. Figure Global Neuroendocrine Tumor Treatment Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
- 6. Figure Global Neuroendocrine Tumor Treatment Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
- 7.Figure Global Neuroendocrine Tumor Treatment Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
- 8. Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 9. Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 10.Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 11.Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 12. Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 13. Figure Everolimus Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 14. Figure Sunitinib Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 15. Figure Lu-Dotatate Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 16. Figure Lanreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 17. Figure Octreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 18. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f



- 19. Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 20.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 21.Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 22. Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 23. Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 24. Figure Everolimus Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 25. Figure Sunitinib Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 26.Figure Lu-Dotatate Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 27. Figure Lanreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 28. Figure Octreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 29. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 30.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 31. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 32. Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 33. Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 34. Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 35.Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 36.Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 37. Figure Everolimus Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 38. Figure Sunitinib Segmentation Market Size (USD Million) 2017-2021f and Year-over-



- year (YOY) Growth (%) 2018-2021f
- 39. Figure Lu-Dotatate Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 40. Figure Lanreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 41. Figure Octreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 42. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 43. Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 44. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 45. Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 46.Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 47. Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 48. Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 49. Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 50. Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 51. Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 52. Figure Everolimus Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 53. Figure Sunitinib Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 54. Figure Lu-Dotatate Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 55. Figure Lanreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 56. Figure Octreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 57. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f



- 58. Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 59. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 60. Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 61. Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 62. Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 63. Figure Everolimus Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 64. Figure Sunitinib Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 65. Figure Lu-Dotatate Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 66. Figure Lanreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 67. Figure Octreotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 68. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 69. Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 70. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 71.Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 72. Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 73. Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 74. Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 75. Figure Everolimus Segmentation Market Size (USD Million) 2017-2021f and Yea



I would like to order

Product name: Neuroendocrine Tumor Treatment Market Status and Trend Analysis 2017-2026

(COVID-19 Version)

Product link: https://marketpublishers.com/r/N33044DAEBB7EN.html

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N33044DAEBB7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



